Microtubule assembly inhibitor

Microtubule assembly inhibitors are a broad class of drugs that disrupt the dynamic behavior of cellular microtubules by either stabilizing or destabilizing their structure. These agents primarily target tubulin proteins—the building blocks of microtubules—thereby interfering with essential processes such as chromosome segregation during mitosis. By blocking proper spindle formation, they induce cell cycle arrest at metaphase/anaphase transition, ultimately triggering programmed cell death. This mechanism underlies their widespread use in cancer chemotherapy where uncontrolled proliferation is characteristic. While highly effective against various malignancies—including breast, ovarian, lung cancers, leukemias, lymphomas—they also have applications outside oncology for diseases like gout and fungal infections due to their impact on cellular division processes more broadly. Despite clinical success, challenges remain regarding toxicity profiles—particularly neurotoxicity—and drug resistance mechanisms that limit long-term efficacy.[1][2][4]

Other names

Mitotic inhibitorMicrotubule inhibitorTubulin inhibitorMicrotubule-targeting agent (MTA)Antimitotic agent

Microtubule assembly inhibitors act by one of two main mechanisms: - **Stabilizing microtubules**: Agents like taxanes bind to β-tubulin and promote excessive stabilization, preventing normal depolymerization required for mitosis. - **Destabilizing microtubules**: Agents like vinca alkaloids and colchicine bind to tubulin at distinct sites, inhibiting polymerization and leading to depolymerization/disassembly of the mitotic spindle. Both mechanisms result in cell cycle arrest at the G2/M phase and trigger apoptosis in rapidly dividing cells such as cancer cells.[2][3]